The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024
Write the words of this act the way you think they should read. Solon shows your change as a redline against the published text and pins it to that exact text, so it can never be applied to wording you did not see.
Change 1
26 Amendment to regulation 49
In regulation 49 (application for grant of UK marketing authorisation or parallel import licence)— (a) after paragraph (1), insert— (1ZA) If the licensing authority determines to grant a UKMA(UK) under paragraph (1), it must determine if one or more of the following criteria are met in relation to the medicinal product— (a) it belongs to a category of medicinal product referred to in Article 3(1) of Regulation (EC) No 726/2004; (b) it belongs to a category of medicinal product referred to in Article 3(2) of Regulation (EC) No 726/2004 and— (i) the medicinal product contains an active substance which, on 20th May 2004, was not authorised in the European Union, or (ii) the licensing authority considers that the medicinal product constitutes a significant therapeutic, scientific or technical innovation or that granting the marketing authorisation is in the interest of patients’ health in the United Kingdom. (1ZB) If the licensing authority determines that one or more of the criteria in paragraph (1ZA) are met, the marketing authorisation granted is a UKMA(UK)(Category 1). (1ZC) If the licensing authority determines that none of the criteria in paragraph (1ZA) are met, the marketing authorisation granted is a UKMA(UK)(Category 2). (1ZD) The licensing authority may grant a UKMA(NI) under Chapter 4 of Title III of the 2001 Directive where there is an application for a marketing authorisation for a medicinal product, unless there is a UKMA(UK), or an application yet to be determined for a UKMA(UK), for the same medicinal product. ; (b) in paragraph (1A)— (i) in the opening words, for “UKMA(GB)” substitute “UKMA(UK)(Category 2)”; (ii) for sub-paragraph (a) substitute— (a) there is in place, or will be at the time the UKMA(UK)(Category 2) is granted, a UKMA(NI) in respect of the product authorising sale or supply in Northern Ireland, ; (c) in paragraph (3)— (i) in sub-paragraph (a), for “a UKMA(UK) or UKMA(NI) must” substitute “a UK marketing authorisation must, subject to sub-paragraph (b),”; (ii) in sub-paragraph (b)— (aa) for “UKMA(GB)” substitute “UKMA(UK)(Category 2)”, (bb) omit paragraph (ii); (d) after paragraph (3), insert— (3ZA) Where a UKMA(UK)(Category 2) is granted under the unfettered access route, any UKMA(NI) granted in relation to the same medicinal product ceases to have effect. ; (e) in paragraph (9), omit sub-paragraph (b) (but not the “or” which follows it).
26 Amendment to regulation 49
In regulation 49 (application for grant of UK marketing authorisation or parallel import licence)— (a) after paragraph (1), insert— (1ZA) If the licensing authority determines to grant a UKMA(UK) under paragraph (1), it must determine if one or more of the following criteria are met in relation to the medicinal product— (a) it belongs to a category of medicinal product referred to in Article 3(1) of Regulation (EC) No 726/2004; (b) it belongs to a category of medicinal product referred to in Article 3(2) of Regulation (EC) No 726/2004 and— (i) the medicinal product contains an active substance which, on 20th May 2004, was not authorised in the European Union, or (ii) the licensing authority considers that the medicinal product constitutes a significant therapeutic, scientific or technical innovation or that granting the marketing authorisation is in the interest of patients’ health in the United Kingdom. (1ZB) If the licensing authority determines that one or more of the criteria in paragraph (1ZA) are met, the marketing authorisation granted is a UKMA(UK)(Category 1). (1ZC) If the licensing authority determines that none of the criteria in paragraph (1ZA) are met, the marketing authorisation granted is a UKMA(UK)(Category 2). (1ZD) The licensing authority may grant a UKMA(NI) under Chapter 4 of Title III of the 2001 Directive where there is an application for a marketing authorisation for a medicinal product, unless there is a UKMA(UK), or an application yet to be determined for a UKMA(UK), for the same medicinal product. ; (b) in paragraph (1A)— (i) in the opening words, for “UKMA(GB)” substitute “UKMA(UK)(Category 2)”; (ii) for sub-paragraph (a) substitute— (a) there is in place, or will be at the time the UKMA(UK)(Category 2) is granted, a UKMA(NI) in respect of the product authorising sale or supply in Northern Ireland, ; (c) in paragraph (3)— (i) in sub-paragraph (a), for “a UKMA(UK) or UKMA(NI) must” substitute “a UK marketing authorisation must, subject to sub-paragraph (b),”; (ii) in sub-paragraph (b)— (aa) for “UKMA(GB)” substitute “UKMA(UK)(Category 2)”, (bb) omit paragraph (ii); (d) after paragraph (3), insert— (3ZA) Where a UKMA(UK)(Category 2) is granted under the unfettered access route, any UKMA(NI) granted in relation to the same medicinal product ceases to have effect. ; (e) in paragraph (9), omit sub-paragraph (b) (but not the “or” which follows it).
One line that says what changes, such as "Halve the dog tax".
Who it helps, what it costs, what it fixes. It is what persuades people to support it.
How this law is officially changed
Solon does not know this law's official route yet. The proposal is recorded all the same, and the route appears here once its source is added.
A proposal here is not law. Support on Solon is evidence that people want the change; the official route says what it takes to make it law.
Sign in to file your proposal. What you have written stays on this page.
Sign in to file itThink it through
Ask what your change would do, who would gain and who would bear a cost, and where something like it is already law. The assistant reads your draft as it stands, cites the law and the studies it finds, and takes no side. What you file stays yours.